
    
      The study will assess three different dosing schedules. A standard 3 plus 3 study design will
      be used. The starting dose for each dosing schedule will be escalated in subsequent groups of
      patients. The study will evaluate safety of increased frequency of AlloStim (TM) dosing and
      anti-tumor effect of the new proposed dose and frequency schedule.
    
  